MMRF President and CEO Walter Capone to Discuss Venture Philanthropy
Norwalk, Conn., March 24, 2015– Kathy Giusti, founder and Chairman of the Board of Directors of the Multiple Myeloma Research Foundation (MMRF) will deliver the keynote address at the 2015 MassBio Annual Meeting on Thursday, March 26, in Cambridge, Mass. Giusti’s address will focus on how collaborative research systems can inject speed and efficiency into the drug discovery and drug development process in order to get treatments to patients faster.
“At the MMRF, we’ve seen what’s possible when we collaborate with extraordinary partners in the biotech and pharmaceutical industry, academia, and the cancer community at-large. Together, the myeloma community has launched seven new treatments and extended the lifespan of patients,” said Giusti. “It is an honor to share with MassBio our innovative model and hope that it accelerates progress in other cancers and diseases.”
On Friday, March 27, Walter Capone, President and CEO of the MMRF, will participate in the panel, “Innovative Ways to Fund Early-Stage Companies,” during the Annual Meeting. Capone will discuss how the MMRF has successfully created opportunities for venture funding to advance its research agenda, including the establishment of a pre-competitive industry consortium to enable open access to clinical and molecular Big Data and the launch of a landmark personalized medicine program.
For more information about the MassBio Annual Meeting and to review the schedule, visit www.massbio.org.
About Kathy Giusti
Kathy Giusti, a multiple myeloma patient, is the Founder of and Executive Chairwoman of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). She also has more than two decades of experience in the pharmaceutical industry, previously holding senior positions at G.D. Searle and Merck. Giusti is widely recognized for establishing innovative research models that have accelerated the development of lifesaving treatments for patients with multiple myeloma and improved the understanding of the biology of deadly diseases. At the heart of this approach is an unwavering commitment to open-access data sharing and patient engagement across the research and care continuum. Her leadership has earned her several prestigious awards and recognitions. Most recently, she was ranked #19 on Fortune Magazine’s Worlds’ 50 Greatest Leaders. In 2013, she was named an Open Science Champion of Change by the White House. In 2011, she was named to the TIME 100 List of the world’s most influential people. Giusti serves on the Harvard Business School Health Advisory Board and previously served on the President’s Council of Advisors on Science and Technology National Cancer Advisory Board and the National Cancer Policy Board. She received her MBA in general management from Harvard Business School.
About Walter Capone
Walter Capone is the President and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF). He has 20 years of pharmaceutical and biotechnology leadership experience in the areas of Commercial Development, Operations, Finance, Marketing and Sales in the United States and internationally. Prior to joining the MMRF, he was the Vice President of Commercial Development and Operations at Progenics Pharmaceuticals. He previously worked at a number of entrepreneurial pharmaceutical and biotechnology ventures throughout the United States and Europe including Trimeris, Triangle Pharmaceuticals and Cyanamid Benelux. He started his career at leading global pharmaceutical companies including Lederle, Wyeth and Bristol-Myers Squibb. He received his BA in International Relations from Brown University and he has an MBA in Finance and International Business from Columbia University Business School.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world’s number-one private funder of multiple myeloma research, the MMRF has raised $275 million since its inception and directs nearly 90% of total budget to research and related programming.